Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 887 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR How Sharing My Story Helps Me Cope With an Advanced Brain... April 15, 2021 Mom Battling Breast Cancer And Daughter With Alopecia Pose Together To... November 7, 2019 2022 ASCO Annual Meeting: Advances in Treating Breast Cancer, Colorectal Cancer, Ewing... June 5, 2022 Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly... April 20, 2026 Load more HOT NEWS A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with... FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma EMA Recommends Extension of Indications for Daratumumab FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer
